Rhythm Pharmaceuticals, Inc. Board of Directors

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Dr. David P. Meeker M.D.

Dr. David P. Meeker M.D.

Chairman, President & CEO

Ms. Sarah Ryan

Ms. Sarah Ryan

Vice President of Sales & Marketing

Dr. Alastair Garfield Ph.D.

Dr. Alastair Garfield Ph.D.

Chief Scientific Officer

Mr. David Connolly

Mr. David Connolly

Head of Investor Relations & Corporate Communications

Mr. Joseph Shulman

Mr. Joseph Shulman

Chief Technical Officer

Mr. Christopher German

Mr. Christopher German

Corporate Controller, Principal Accounting Officer & Executive Director

Mr. Jim Flaherty

Mr. Jim Flaherty

Senior VP & General Counsel

Mr. Yann Mazabraud

Mr. Yann Mazabraud

Executive VP & Head of International

Ms. Jennifer Lee

Ms. Jennifer Lee

Executive VP & Head of North America

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.